PMID- 9400492
OWN - NLM
STAT- MEDLINE
DCOM- 19971229
LR  - 20190621
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 159
IP  - 1
DP  - 1998 Jan
TI  - Does topical instillation therapy influence chromosomal aberrations in 
      superficial bladder cancer?
PG  - 265-9
AB  - PURPOSE: Patients with a high risk for superficial bladder cancer are treated by 
      topical immuno-or chemotherapy after transurethral resection to reduce the chance 
      of recurrence and/or progression. The aim of this study was to analyse if 
      cytogenetical abnormalities, which are known to be constantly related to bladder 
      cancer, are modified or eliminated by topical immuno- or chemotherapy. MATERIALS 
      AND METHODS: Using fluorescence in situ hybridization (FISH), the influence of 
      topical instillation therapy with Bacillus Calmette-Guerin (BCG) and Mitomycin C 
      (MMC) on numerical aberrations of chromosomes 7, 9 and 17 was investigated in 25 
      patients with transitional cell cancer (TCC) of the bladder. Data were compared 
      with histological and clinical outcome. Fifteen TCC patients with similar 
      histological criteria without instillation therapy served as controls. Median 
      follow-up was 30 +/- 2 months. RESULTS: After BCG treatment 10 of 15 patients 
      (66.6%) developed recurrent and 2/15 (13.3%) progressive disease. Three of 15 
      patients (20.0%) had no evidence of disease. Numerical aberrations did not change 
      in 8 of the 15 BCG patients (53.3%) and changed to a more aggressive pattern in 
      40.0% (6/15). Five of 10 MMC treated patients (50.0%) developed a recurrent 
      tumor, 2/10 (20.0%) progressed and 3/10 (30.0%) had no evidence of disease. Four 
      of 10 (40.0%) of these patients showed stable and 5/10 (50.0%) progressive 
      chromosomal patterns. Only one patient in each group with primary chromosomal 
      alterations changed to a regular diploid chromosomal pattern after therapy 
      according to a complete clinical remission. CONCLUSION: Even though topical 
      immuno- and chemotherapy may be useful to delay recurrence and progression, 
      chromosomal patterns remain basically unstable.
FAU - Pycha, A
AU  - Pycha A
AD  - Department of Urology, University of Vienna, Austria.
FAU - Mian, C
AU  - Mian C
FAU - Hofbauer, J
AU  - Hofbauer J
FAU - Haitel, A
AU  - Haitel A
FAU - Wiener, H
AU  - Wiener H
FAU - Marberger, M
AU  - Marberger M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (BCG Vaccine)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Administration, Intravesical
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibiotics, Antineoplastic/*administration & dosage
MH  - BCG Vaccine/*administration & dosage
MH  - Carcinoma, Transitional Cell/*genetics/*therapy
MH  - Chromosome Aberrations/*genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Chromosomes, Human, Pair 7/*genetics
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitomycin/*administration & dosage
MH  - Urinary Bladder Neoplasms/*genetics/*therapy
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - S0022-5347(01)64079-5 [pii]
AID - 10.1016/s0022-5347(01)64079-5 [doi]
PST - ppublish
SO  - J Urol. 1998 Jan;159(1):265-9. doi: 10.1016/s0022-5347(01)64079-5.